SPH7854 / Shanghai Pharma - LARVOL DELTA

SPH7854, a gut-limited RORγt antagonist, ameliorates TNBS-induced experimental colitis in rat. (PubMed, Int Immunopharmacol) - "SPH7854, especially at 15 mg/kg, significantly alleviated symptoms and improved macroscopic signs and microscopic structure in rat colitis, with decreased colonic mucosal levels of IL-17A, IL-6, tumor necrosis factor α (TNFα), monocyte chemoattractant protein-1 (MCP-1) and myeloperoxidase (MPO). These evidences indicated that blockade of RORγt activity via a gut-limited antagonist may be an effective and safe therapeutic strategy for IBD treatment."

Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Immunology • Inflammatory Bowel Disease • Lymphoma • Oncology • CCL2 • CD4 • IL17A • IL6 • MPO • TNFA

A Clinical Study of SPH7854 Granules in Healthy Subjects. (clinicaltrials.gov) - P1 | N=111 | Recruiting | Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease